Management of Castration-Resistant Prostate Cancer
We believe that the field of prostate cancer has made tremendous strides in treating CRPC. As data from ongoing trials mature over this and next year, we expect to see a whole host of new options for this late-stage malignancy. It appears that drugs like MDV3100 and radium-223 have the potential to join cabazitaxel in becoming second-line treatments after docetaxel-based chemotherapy failure in CRPC patients. We also believe that agents like sipuleucel-T may be used significantly earlier in the disease process.
Expert Commentary
We believe that the field of prostate cancer has made tremendous strides in treating CRPC. As data from ongoing trials mature over this and next year, we expect to see a whole host of new options for this late-stage malignancy. It appears that drugs like MDV3100 and radium-223 have the potential to join cabazitaxel in becoming second-line treatments after docetaxel-based chemotherapy failure in CRPC patients. We also believe that agents like sipuleucel-T may be used significantly earlier in the disease process.
SHARE
![Pediatric Supportive Care (PDQ®): Supportive care - Patient Information [NCI]-Overview](https://cdnus.oss-us-west-1.aliyuncs.com/libs/images/NewsJpg/cate_6/072_215x160.jpg)
